Search

Two projects from a portfolio of 57 that the Tri-I TDI has supported have “graduated” with the demonstration that the compounds under study work in preclinical contexts. These compounds are now ready for the next phase of therapeutic development – a phase intended to lead to investigational new drugs. A third project, which originated at Weill Cornell Medicine, is expected to move forward later this month. These projects are candidates for advancement into Bridge Medicines, Inc., a for-profit company established in 2016 by the three Tri-I TDI academic founders, Takeda, and two investment firms – Bay City Capital and Deerfield Management – designed to take Tri-I TDI projects into readiness for clinical trials over a two- to three-year time frame.

Animal model research from MSK has shown for the first time that fasting can reprogram the metabolism of natural killer cells, helping them to survive in the harsh environment in and around tumors, while also improving their cancer-fighting ability.

Doctors are developing treatment strategies that target the androgen receptor, which is found in many triple-negative breast cancers.

Ten scientists are poised to receive their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Their years of dedication and training will be recognized on May 15, 2024, as part of Memorial Sloan Kettering’s 45th annual academic convocation.

Scientists are looking to exploit defects in DNA repair as an Achilles’ heel in cancer.

At any given time, close to 700 teenagers and young adults are in active treatment at Memorial Sloan Kettering. On March 18, MSK opened a hip new space dubbed the Lounge as part of the newly launched Teen and Young Adult Program designed to give these young patients the support they need during a turbulent time.

MSK was recently in the news regarding our relationship with a technology spin-off company called Paige.AI.

MSK achieved status as a Magnet®-recognized organization, an esteemed honor for nursing excellence.